I would venture the guess that the real issue for the recent drop in price, and the insider buying, is that some kind of financing plan is being worked on.
GTCB will be needing funds in 2008 in order to commercialize Atryn. As an orphan drug they will not be generating mega-millions in income. However, they will need to set up some distribution and sales operations, best hiring an outside rep firm rather than a sales force.
Then there is the continued development. This all takes more cash. I just hope that they do it in a way that protects the future for the shareholders.
Look into the Matritech story if you need a better understanding of what I mean.
They had an approved product with slowly growing sales and sold the firm to protect their insider loans and parachutes.
I'm not saying this is happening here, but, one can never tell. I hope to buy in at some point, but, am waiting to see how the future financing is done.
Market Data 
Markets 
AI
